Paromamine

Paromamine

SCHEMBL2736463

NC1CC(N)C(OC2OC(CO)C(O)C(O)C2N)C(O)C1O

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LRAT O95237 2/20 0.79
LMNA P02545 1/20 0.72
KDM4E B2RXH2 1/20 0.72
ALOX15 P16050 1/20 0.72
TSHR P16473 2/20 0.69
HSD17B10 Q99714 1/20 0.69
MEN1 O00255 2/20 0.67
TRPV1 Q8NER1 1/20 0.67
GJA1 P17302 1/20 0.62
GJB2 P29033 1/20 0.62
CYP2C9 P11712 1/20 0.62
KMT2A Q03164 1/20 0.62
ALDH1A1 P00352 1/20 0.62
BLM P54132 1/20 0.62
RECQL P46063 1/20 0.62
TDP1 Q9NUW8 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Paromamine SCHEMBL15251517 1.00 LRAT (0.79) LRATLMNAKDM4EALOX15TSHR
Paromamine SCHEMBL18616648 1.00 LRAT (0.79) LRATLMNAKDM4EALOX15TSHR
Paromamine SCHEMBL14495298 1.00 LRAT (0.79) LRATLMNAKDM4EALOX15TSHR
Paromamine SCHEMBL22476648 1.00 LRAT (0.79) LRATLMNAKDM4EALOX15TSHR
Paromamine SCHEMBL13873360 1.00 LRAT (0.79) LRATLMNAKDM4EALOX15TSHR
Paromamine SCHEMBL12168155 1.00 LRAT (0.79) LRATLMNAKDM4EALOX15TSHR
Paromamine SCHEMBL8812240 1.00 LRAT (0.79) LRATLMNAKDM4EALOX15TSHR
Paromamine SCHEMBL30804048 0.93 BLM (0.72) LRATLMNAKDM4EALOX15TSHR
SCHEMBL22047136 0.91 LRAT (0.66) LRATLMNAKDM4EALOX15TSHR
SCHEMBL2538392 0.91 ALOX15 (0.81) LRATLMNAKDM4EALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11786539-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders ELOXX PHARMACEUTICALS LTD. (IL) 2023-10-17 US disclosed
US-20230181612-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2023-06-15 US disclosed
US-11673907-B2 Modular synthesis of aminoglycosides REVAGENIX, INC. (US) 2023-06-13 US disclosed
US-20230167148-A1 MODULAR SYNTHESIS OF AMINOGLYCOSIDES REVAGENIX, INC. 2023-06-01 US disclosed
US-20220411456-A1 MODULAR SYNTHESIS OF AMINOGLYCOSIDES REVAGENIX, INC. (US) 2022-12-29 US disclosed
US-11306115-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders ELOXX PHARMACEUTICALS LTD. (IL) 2022-04-19 US disclosed
US-20220033428-A1 LARGE SCALE PREPARATION OF PSEUDO-TRISACCHARIDE AMINOGLYCOSIDES AND OF INTERMEDIATES THEREOF ELOXX PHARMACEUTICALS LTD. (IL) 2022-02-03 US disclosed
US-11136345-B2 Large scale preparation of pseudo-trisaccharide aminoglycosides and of intermediates thereof ELOXX PHARMACEUTICALS LTD. (IL) 2021-10-05 US disclosed
US-20210220380-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2021-07-22 US disclosed
US-10973839-B2 Aminoglycosides and uses thereof in treating genetic disorders TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2021-04-13 US disclosed
US-9616079-B2 Aminoglycosides and uses thereof in treating genetic disorders TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2017-04-11 US disclosed
WO-2017037717-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2017-03-09 WO disclosed
US-8729035-B2 Synthesis of novel neamine derivatives and use thereof as antibacterial agents UNIVERSITE JOSEPH FOURIER (FR) 2014-05-20 US disclosed
US-8729035-B2 Synthesis of novel neamine derivatives and use thereof as antibacterial agents UNIVERSITE JOSEPH FOURIER (FR) 2014-05-20 US disclosed
US-8088626-B2 Chiral selectors for separating enantiomers of a compound University Joseph Fourier (Grenoble 1) (FR) 2012-01-03 US disclosed
US-20100311680-A1 SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS UNIVERSITE JOSEPH FOURIER (FR) 2010-12-09 US disclosed
US-20100311680-A1 SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS UNIVERSITE JOSEPH FOURIER (FR) 2010-12-09 US disclosed
US-20100144045-A1 CHIRAL SELECTORS FOR SEPARATING ENANTIOMERS OF A COMPOUND UNIVERISTE JOSEPH FOURIER (GRENOBLE 1) (FR) 2010-06-10 US disclosed
WO-2009095588-A2 SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS UNIVERSITE JOSEPH FOURIER (FR) 2009-08-06 WO disclosed
WO-2008132340-A2 CHIRAL SELECTORS FOR SEPARATING ENANTIOMERS OF A COMPOUND UNIVERSITE JOSEPH FOURIER (GRENOBLE 1) (FR) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673907-B2 Modular synthesis of aminoglycosides MRPL21, COASY, AARS1 LRAT 945/4885LMNA 2679/4885KDM4E 3762/4885
US-20100144045-A1 CHIRAL SELECTORS FOR SEPARATING ENANTIOMERS OF A COMPOUND CD2, CD22, CA2 LRAT 2404/4885LMNA 4394/4885KDM4E 2950/4885
US-20210220380-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS UPF1, UGGT1, ARSA LRAT 2094/4885LMNA 2467/4885KDM4E 3335/4885
US-11306115-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders UPF1, IDUA, UGGT1 LRAT 2020/4885LMNA 2417/4885KDM4E 3531/4885
US-11786539-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders UPF1, UGGT1, ARSA LRAT 2094/4885LMNA 2467/4885KDM4E 3335/4885
US-20100311680-A1 SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS HRH3, HRH4, H1-4 LRAT 1193/4885LMNA 4185/4885KDM4E 2234/4885
US-11136345-B2 Large scale preparation of pseudo-trisaccharide aminoglycosides and of intermediates thereof OSTC, TREH, GPI LRAT 923/4885LMNA 3303/4885KDM4E 4164/4885
US-20220033428-A1 LARGE SCALE PREPARATION OF PSEUDO-TRISACCHARIDE AMINOGLYCOSIDES AND OF INTERMEDIATES THEREOF OSTC, TREH, GPI LRAT 923/4885LMNA 3303/4885KDM4E 4164/4885
US-20230167148-A1 MODULAR SYNTHESIS OF AMINOGLYCOSIDES MRPL21, COASY, AARS1 LRAT 945/4885LMNA 2679/4885KDM4E 3762/4885
US-10973839-B2 Aminoglycosides and uses thereof in treating genetic disorders AARS1, GARS1, UPF1 LRAT 1724/4885LMNA 2154/4885KDM4E 3261/4885
US-20220411456-A1 MODULAR SYNTHESIS OF AMINOGLYCOSIDES MRPL21, COASY, AARS1 LRAT 945/4885LMNA 2679/4885KDM4E 3762/4885
US-20230181612-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS UPF1, NSUN3, AARS1 LRAT 2253/4885LMNA 768/4885KDM4E 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.